AZOR

LOE Approaching

amlodipine besylate and olmesartan medoxomil

NDAORALTABLET
Approved
Sep 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5

Mechanism of Action

. Azor is a combination of two antihypertensive drugs: a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker), amlodipine besylate, and an angiotensin II receptor blocker, olmesartan medoxomil. The amlodipine component of Azor inhibits the transmembrane influx of…

Clinical Trials (5)

NCT02849873Phase 1Completed

Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream

Started Jun 2016
NCT02938494Phase 2Completed

Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris

Started Nov 2015
NCT02325518Phase 4Completed

Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution

Started Dec 2014
218 enrolled
Open-Angle GlaucomaOcular Hypertension
NCT01019603Phase 1Completed

A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris

Started Oct 2009
30 enrolled
Acne Vulgaris
NCT01016977Phase 4Completed

A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris

Started Oct 2009
40 enrolled
Acne Vulgaris